On July 24, 2026, Zevra Therapeutics (NASDAQ: ZVRA) shares fell approximately 24% after the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa, for Niemann-Pick disease type C. Investors who suffered losses tied to the ZVRA drop are encouraged to submit your loss information now or contact Levi & Korsinsky, LLP | (212) 363-7500 | www.zlk.com
The CHMP decision concerned Zevra’s arimoclomol application in Europe. The Company stated that it intends to request a re-examination of the opinion and continue providing arimoclomol to eligible patients through its global Expanded Access Program.
Levi & Korsinsky is investigating potential securities law violations involving Zevra’s public statements concerning arimoclomol’s regulatory pathway. The investigation follows the July 24 regulatory decision and the related trading losses suffered by ZVRA shareholders.
If you lost money in ZVRA following the July 24 regulatory news, request a loss review today or call (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP — Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report.
Frequently Asked Questions About the ZVRA Investigation
Q: What is the ZVRA investigation about? A: The investigation concerns Zevra Therapeutics (ZVRA) and public statements regarding arimoclomol, branded Meplyffa, for Niemann-Pick disease type C. Shares fell approximately 24% on July 24, 2026 after the EMA’s CHMP issued a negative opinion on the Marketing Authorization Application.
Q: Who is eligible to participate in the ZVRA investigation? A: Investors who purchased ZVRA securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.
Q: How much did ZVRA stock drop? A: Zevra shares fell approximately 24% after the July 24, 2026 CHMP negative opinion concerning arimoclomol for Niemann-Pick disease type C.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any later sale dates and prices.
Q: What if I already sold my ZVRA shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased and whether you suffered documented losses, not whether you still hold the shares.
Q: What if my ZVRA losses are small — is it still worth contacting a lawyer? A: Yes. There is no minimum loss amount required to participate in the investigation.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If later proceedings occur, most affected investors are not required to appear.
Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting proceedings are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.
Attorney Advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260729727890/en/
Media gallery
